Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSeveral medicines can interact with Mounjaro (tirzepatide), mainly because it slows the rate at which food (and other drugs) leave the stomach. The Mounjaro Summary of Product Characteristics, published on the electronic Medicines Compendium (eMC), flags this gastric-emptying effect as the primary mechanism behind most interactions; official guidance identifies oral contraceptives and medicines with narrow therapeutic windows as the categories needing closest attention. That said, interaction lists can feel overwhelming when you first read them. If you're working through your current medicines and wondering what this means for you personally, that is exactly the kind of question a prescriber is there to answer — not a search engine. Mounjaro is a prescription-only medicine, and a clinician assesses your full medication history before any treatment is approved.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide activates two gut-hormone receptors (GIP and GLP-1) and one practical consequence is that the stomach empties more slowly than usual. For most foods this is part of the intended effect: you feel full sooner and for longer. For orally administered medicines, though, a slower transit time can shift the absorption curve. A drug that normally reaches its peak concentration in the bloodstream within an hour may take considerably longer, or, if it is absorbed primarily in the stomach rather than the small intestine, its total absorption may change.
The Mounjaro SmPC addresses this directly, recommending that prescribers consider the potential effect on co-administered oral medicines, particularly those where timing of absorption matters clinically. You can review the full prescribing information on the electronic Medicines Compendium (eMC), where the Mounjaro SmPC is published in full. The British National Formulary also lists interaction alerts for tirzepatide under the BNF tirzepatide entry, which your GP or pharmacist can cross-reference against your specific medicines.
It is worth being clear about what this does not mean: the interaction mechanism is not unique to Mounjaro and is shared, to varying degrees, by other GLP-1 medicines. It does not make Mounjaro incompatible with most common medicines. It does mean timing and monitoring matter, and that a thorough medicines review before starting is genuinely important rather than a bureaucratic box-tick. Our overview of Mounjaro as a medicine covers the broader pharmacology if that context is helpful.
NHS guidance is specific on this point. Women taking an oral contraceptive pill should use an additional non-oral method of contraception (condoms, for example) during the first four weeks of Mounjaro treatment, and for four weeks after every dose increase. The reason is straightforward: if the pill is absorbed more slowly or less completely because gastric emptying is delayed, its contraceptive efficacy may be reduced. This is not a theoretical concern included as a legal precaution; it reflects the mechanism clearly enough that prescribers are expected to counsel patients about it.
The guidance comes from NHS England's published information on weight management injections, which is the same resource GP practices are directed to. It also notes that the same evidence-based concern does not currently apply to injectable or other non-oral contraceptive methods. If you use a contraceptive implant, hormonal coil, patch or injection, your prescriber will still want to know, but the additional-method recommendation is specific to oral pills.
This is one of the areas where starting a conversation early matters. There is a more detailed look at the contraception question on the page covering drug interactions with Mounjaro specifically, which goes into further practical detail.
Some drugs require blood concentrations to stay within a tight range, too low and they stop working, too high and they cause harm. Warfarin is the most familiar example in the UK: small changes in absorption or clearance can push INR outside the safe range. Certain antiepileptic medicines, digoxin, and some thyroid medications sit in the same general category.
This does not mean Mounjaro is contraindicated alongside these drugs. It means that when treatment starts (or when a dose increase happens) the prescriber and the patient's wider clinical team need to be aware, so that monitoring can be adjusted if needed. Your INR checks may need to happen a little more frequently in the first weeks, for instance. The clinical decision about whether that monitoring is feasible belongs to the prescriber who knows your full history, not to a general web page.
For a broader picture of medicines that require particular consideration, the page on medicines to avoid with Mounjaro covers the contraindication and caution list in more detail. And if you are already on Mounjaro and a new medicine is being added to your regimen, telling both prescribers is the simplest safeguard, a fact worth flagging because it is occasionally overlooked when prescribing happens across different services.
The most protective step is straightforward: a complete list. That means prescription medicines, yes, but also over-the-counter analgesics, heartburn remedies, supplements (omega-3 at high doses affects INR; St John's Wort interacts with a wide range of drugs), and any hormonal contraception or HRT. HRT is worth mentioning explicitly, NHS England notes that transdermal HRT (patches or gels) may be preferable to oral forms while on tirzepatide, for the same absorption reasons as the pill, and that this is something to discuss with your doctor before or at the start of treatment. If you are unsure whether something you take is relevant, the page on whether Mounjaro interacts with medications walks through the question in a way that is easy to apply to your own situation.
At nume, a GPhC-registered prescriber personally reads every consultation (your medication list included) before any treatment is approved. There is no algorithm passing things through. If something in your history prompts a clinical question, you will hear from the prescribing team rather than receive a default approval. Details of how our clinical review works are on the about us page, and our lead prescriber's background is outlined on the clinical team profile.
If you have questions about a specific interaction not covered here, the FAQs address some common ones, or you can reach the team directly via the contact page. For a fuller picture of how Mounjaro works as a treatment, the Mounjaro overview is a good starting point. And if you are weighing up the cost side of things alongside clinical questions, the Mounjaro prices page sets out what private treatment typically involves. When you are ready to have your situation properly assessed, you can check your eligibility with a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.